Abbott Laboratories' MedTech Business Sustains Momentum Amid Nutrition Weakness, UBS Says

MT Newswires Live01-24 04:15

Abbott Laboratories' (ABT) fourth-quarter results were weighed down by weakness in its Nutrition business, but the stock's pullback presents an opportunity, supported by resilient earnings and strong MedTech growth, UBS Securities said in a Thursday note.

UBS noted that despite Abbott's organic sales growth, excluding COVID, slowing to 3.8% in the fourth quarter, it remains confident in management's 2026 organic growth guidance of 6.5% to 7.5%, citing underappreciated MedTech tailwinds.

The brokerage highlighted a rebound in electrophysiology following the US Volt launch, potential upside from an upcoming large left atrial appendage closure trial, and strong demand for Libre continuous glucose monitoring products.

While uncertainty remains in Nutrition, which accounts for about 20% of sales, UBS said MedTech strength and accelerating growth into 2026 support a more positive view on the stock.

UBS maintained its buy rating with a price target of $158.

Shares of Abbott Laboratories were down 1.3% in recent Friday trading.

Price: 107.04, Change: -1.57, Percent Change: -1.45

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment